학술논문
How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study
Document Type
article
Author
Özcan Başaran; Volkan Doğan; Kadir Uğur Mert; Bülent Özlek; Eda Özlek; Oğuzhan Çelik; Cem Çil; İbrahim Halil Özdemir; İbrahim Rencüzoğulları; Fatma Özpamuk Karadeniz; Mehmet Tekinalp; Lütfü Aşkın; Selami Demirelli; Erkan Gencer; Lütfü Bekar; Müjdat Aktaş; Mübariz Murat Resulzade; Macit Kalçık; Gökhan Aksan; Göksel Çinier; Kadriye Halil Akay; Nihat Pekel; Gurbet Özge Mert; Utku Şenol; Vahit Demir; Sinan İnci; Emir Derviş; Murat Biteker; Meral Kayıkçıoğlu
Source
Anatolian Journal of Cardiology, Vol 27, Iss 2, Pp 78-87 (2023)
Subject
Language
English
ISSN
2149-2271
Abstract
Background: The recent 2019 European Society of Cardiology/European Atherosclerosis Society practice guidelines introduced a new risk categorization for patients with diabetes. We aimed to compare the implications of the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines with regard to the lipid-lowering treatment use, low-density lipoprotein cholesterol goal attainment rates, and the estimated proportion of patients who would be at goal in an ideal setting. Methods: Patients with diabetes were classified into 4 risk categories according to 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines from the database of EPHESUS (cross-sectional, observational, countrywide registry of cardiology outpatient clinics) study. The use of lipid-lowering treatment and low-density lipoprotein cholesterol goal attainment rates were then compared according to previous and new guidelines. Results: This analysis included a total of 873 diabetic adults. Half of the study population (53.8%) were on lipid-lowering treatment and almost one-fifth (19.1%) were on high-intensity statins. While low-density lipoprotein cholesterol goal was achieved in 19.5% and 7.5% of patients, 87.4% and 69.6% would be on target if their lipid-lowering treatment was intensified according to 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society lipid guidelines, respectively. The new target